Trader consensus implies about a 50% chance of DEA rescheduling marijuana from Schedule I to Schedule III by December 31, 2026, but only 14% odds for June 30, driven by stalled rulemaking despite President Trump's December 2025 executive order directing Attorney General Pam Bondi to expedite the process based on HHS's prior scientific recommendation. The DEA's April 7 filing, its fifth status report, confirmed no advancement amid pending administrative appeals, prompting Democratic Rep. Steve Cohen's March 27 letter demanding a timeline from Bondi and DEA Administrator Terry Cole. Trump advisor Roger Stone alleged on April 10 that internal administration resistance is delaying completion, underscoring procedural hurdles with no hearings or deadlines set.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено$310,083 Обс.

June 30
13%

December 31
37%
$310,083 Обс.

June 30
13%

December 31
37%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Ринок відкрито: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Trader consensus implies about a 50% chance of DEA rescheduling marijuana from Schedule I to Schedule III by December 31, 2026, but only 14% odds for June 30, driven by stalled rulemaking despite President Trump's December 2025 executive order directing Attorney General Pam Bondi to expedite the process based on HHS's prior scientific recommendation. The DEA's April 7 filing, its fifth status report, confirmed no advancement amid pending administrative appeals, prompting Democratic Rep. Steve Cohen's March 27 letter demanding a timeline from Bondi and DEA Administrator Terry Cole. Trump advisor Roger Stone alleged on April 10 that internal administration resistance is delaying completion, underscoring procedural hurdles with no hearings or deadlines set.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання